Association between SETBP1 overexpression and clinical and genetic parameters in 192 patients with AML at diagnosis
| . | No. of cases . | SETBP1−, no. (%) . | No. SETBP1+, no. (%) . | P . |
|---|---|---|---|---|
| SETBP1 | 192 | 139 (72.4) | 53 (27.6) | |
| Sex | 187 | 136 | 51 | .511 |
| Male | 99 | 70 (70.7) | 29 (29.3) | |
| Female | 88 | 66 (75) | 22 (25) | |
| Age | 183 | 136 | 47 | .219 |
| Less than 60 years | 92 | 72 (78.3) | 20 (21.7) | |
| More than 60 years | 91 | 64 (70.3) | 27 (29.7) | |
| Complete remission | 128 | 180 | 50 | .196 |
| No | 47 | 33 (70.2) | 14 (29.8) | |
| Yes | 81 | 65 (80.2) | 16 (19.8) | |
| Secondary AML | 156 | 247 | 56 | .354 |
| No | 130 | 101 (77.7) | 29 (22.3) | |
| Yes | 26 | 18 (69.2) | 8 (30.8) | |
| Prognostic group | 192 | 139 | 53 | .006* |
| Good | 29 | 22 (76) | 7 (24) | |
| Intermediate | 92 | 75 (82.5) | 17 (18.5) | |
| Poor | 71 | 42 (59.2) | 29 (40.8) | |
| Cytogenetic group | 192 | 139 | 53 | |
| Normal karyotype | .010* | |||
| Yes | 63 | 53 (84) | 10 (16) | |
| No | 128 | 85 (66.4) | 43 (33.6) | |
| Trisomy 8 | .943 | |||
| Yes | 18 | 13 (72.2) | 5 (27.8) | |
| No | 163 | 119 (73) | 44 (27) | |
| Chromosome 18 aberrations | .031* | |||
| Yes | 11 | 5 (45.4) | 6 (54.6) | |
| No | 169 | 127 (75) | 42 (25) | |
| Monosomy 7 | .007* | |||
| Yes | 27 | 14 (51.9) | 13 (48.1) | |
| No | 155 | 119 (76.8) | 36 (23.2) | |
| der(7q) | .318 | |||
| Yes | 16 | 10 (62.5) | 6 (37.5) | |
| No | 166 | 123 (74.1) | 43 (25.9) | |
| WT1 overexpression | 137 | 108 | 29 | .345 |
| No | 22 | 19 (86.7) | 3 (13.6) | |
| Yes | 115 | 89 (77.4) | 26 (22.6) | |
| EVI1 overexpression | 172 | 126 | 46 | .001* |
| No | 132 | 108 (81.8) | 24 (18.2) | |
| Yes | 40 | 18 (45) | 22 (55) | |
| MDS1EVI1 overexpression | 152 | 109 | 43 | .012* |
| No | 138 | 103 (74.6) | 35 (25.4) | |
| Yes | 14 | 6 (42.9) | 8 (57.1) | |
| NPM1 mutated and FLT3 wt | 32 | 28 | 4 | .014* |
| No | 12 | 8 (66.7) | 4 (33.3) | |
| Yes | 20 | 20 (100) | 0 (0.0) | |
| FLT3-ITD | 125 | 100 | 25 | .760 |
| No | 99 | 78 (78.8) | 21 (21.2) | |
| Yes | 26 | 22 (84.6) | 4 (15.4) |
| . | No. of cases . | SETBP1−, no. (%) . | No. SETBP1+, no. (%) . | P . |
|---|---|---|---|---|
| SETBP1 | 192 | 139 (72.4) | 53 (27.6) | |
| Sex | 187 | 136 | 51 | .511 |
| Male | 99 | 70 (70.7) | 29 (29.3) | |
| Female | 88 | 66 (75) | 22 (25) | |
| Age | 183 | 136 | 47 | .219 |
| Less than 60 years | 92 | 72 (78.3) | 20 (21.7) | |
| More than 60 years | 91 | 64 (70.3) | 27 (29.7) | |
| Complete remission | 128 | 180 | 50 | .196 |
| No | 47 | 33 (70.2) | 14 (29.8) | |
| Yes | 81 | 65 (80.2) | 16 (19.8) | |
| Secondary AML | 156 | 247 | 56 | .354 |
| No | 130 | 101 (77.7) | 29 (22.3) | |
| Yes | 26 | 18 (69.2) | 8 (30.8) | |
| Prognostic group | 192 | 139 | 53 | .006* |
| Good | 29 | 22 (76) | 7 (24) | |
| Intermediate | 92 | 75 (82.5) | 17 (18.5) | |
| Poor | 71 | 42 (59.2) | 29 (40.8) | |
| Cytogenetic group | 192 | 139 | 53 | |
| Normal karyotype | .010* | |||
| Yes | 63 | 53 (84) | 10 (16) | |
| No | 128 | 85 (66.4) | 43 (33.6) | |
| Trisomy 8 | .943 | |||
| Yes | 18 | 13 (72.2) | 5 (27.8) | |
| No | 163 | 119 (73) | 44 (27) | |
| Chromosome 18 aberrations | .031* | |||
| Yes | 11 | 5 (45.4) | 6 (54.6) | |
| No | 169 | 127 (75) | 42 (25) | |
| Monosomy 7 | .007* | |||
| Yes | 27 | 14 (51.9) | 13 (48.1) | |
| No | 155 | 119 (76.8) | 36 (23.2) | |
| der(7q) | .318 | |||
| Yes | 16 | 10 (62.5) | 6 (37.5) | |
| No | 166 | 123 (74.1) | 43 (25.9) | |
| WT1 overexpression | 137 | 108 | 29 | .345 |
| No | 22 | 19 (86.7) | 3 (13.6) | |
| Yes | 115 | 89 (77.4) | 26 (22.6) | |
| EVI1 overexpression | 172 | 126 | 46 | .001* |
| No | 132 | 108 (81.8) | 24 (18.2) | |
| Yes | 40 | 18 (45) | 22 (55) | |
| MDS1EVI1 overexpression | 152 | 109 | 43 | .012* |
| No | 138 | 103 (74.6) | 35 (25.4) | |
| Yes | 14 | 6 (42.9) | 8 (57.1) | |
| NPM1 mutated and FLT3 wt | 32 | 28 | 4 | .014* |
| No | 12 | 8 (66.7) | 4 (33.3) | |
| Yes | 20 | 20 (100) | 0 (0.0) | |
| FLT3-ITD | 125 | 100 | 25 | .760 |
| No | 99 | 78 (78.8) | 21 (21.2) | |
| Yes | 26 | 22 (84.6) | 4 (15.4) |
AML indicates acute myeloid leukemia.
Significant values.